{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:58:06Z","timestamp":1791140286820,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115952"],"award-info":[{"award-number":["115952"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115975"],"award-info":[{"award-number":["115975"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115985"],"award-info":[{"award-number":["115985"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish ISCIII, Acci\u00f3n Estrat\u00e9gica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdirecci\u00f3n General de Evaluaci\u00f3n and the Fondo Europeo de Desarrollo Regional","award":["PI13\/02434"],"award-info":[{"award-number":["PI13\/02434"]}]},{"name":"Spanish ISCIII, Acci\u00f3n Estrat\u00e9gica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdirecci\u00f3n General de Evaluaci\u00f3n and the Fondo Europeo de Desarrollo Regional","award":["PI16\/01861"],"award-info":[{"award-number":["PI16\/01861"]}]},{"name":"Spanish ISCIII, Acci\u00f3n Estrat\u00e9gica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdirecci\u00f3n General de Evaluaci\u00f3n and the Fondo Europeo de Desarrollo Regional","award":["PI19\/01240"],"award-info":[{"award-number":["PI19\/01240"]}]},{"name":"Spanish ISCIII, Acci\u00f3n Estrat\u00e9gica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdirecci\u00f3n General de Evaluaci\u00f3n and the Fondo Europeo de Desarrollo Regional","award":["PI19\/01301"],"award-info":[{"award-number":["PI19\/01301"]}]},{"name":"Spanish ISCIII, Acci\u00f3n Estrat\u00e9gica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdirecci\u00f3n General de Evaluaci\u00f3n and the Fondo Europeo de Desarrollo Regional","award":["PI22\/00258"],"award-info":[{"award-number":["PI22\/00258"]}]},{"name":"Spanish ISCIII, Acci\u00f3n Estrat\u00e9gica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdirecci\u00f3n General de Evaluaci\u00f3n and the Fondo Europeo de Desarrollo Regional","award":["PI22\/01403"],"award-info":[{"award-number":["PI22\/01403"]}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["PMP22\/00022"],"award-info":[{"award-number":["PMP22\/00022"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015496","name":"CIBERNED","doi-asserted-by":"crossref","award":["CB06\/05\/2004"],"award-info":[{"award-number":["CB06\/05\/2004"]}],"id":[{"id":"10.13039\/501100015496","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015496","name":"CIBERNED","doi-asserted-by":"crossref","award":["CB18\/05\/00010"],"award-info":[{"award-number":["CB18\/05\/00010"]}],"id":[{"id":"10.13039\/501100015496","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Joint program for neurodegenerative diseases","award":["AC19\/00097"],"award-info":[{"award-number":["AC19\/00097"]}]},{"name":"Agency for Innovation and Entrepreneurship","award":["PR067\/21"],"award-info":[{"award-number":["PR067\/21"]}]},{"name":"ISCIII Subdirecci\u00f3n General de Evaluaci\u00f3n and the Fondo Europeo de Desarrollo Regional","award":["PI17\/01474"],"award-info":[{"award-number":["PI17\/01474"]}]},{"name":"Programa Misiones de I+D en Inteligencia Artificial de la Secretar\u00eda de Estado de Digitalizaci\u00f3n e Inteligencia Artificial (SEDIA) del Ministerio de Asuntos Econ\u00f3micos y Transformaci\u00f3n Digital","award":["TARTAGLIA"],"award-info":[{"award-number":["TARTAGLIA"]}]},{"DOI":"10.13039\/100018694","name":"HORIZON EUROPE Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["796706"],"award-info":[{"award-number":["796706"]}],"id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Subdirecci\u00f3n General de Evaluaci\u00f3n and the Fondo Europeo de Desarrollo Regional","award":["PI19\/00335"],"award-info":[{"award-number":["PI19\/00335"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Amyloid PET imaging is capable of measuring brain amyloid load in vivo. The aim of this study is to assess the relationship of the baseline amyloid with its accumulation over time and with cognition in individuals with subjective cognitive decline (SCD), giving a focus on those below A\u03b2 positivity thresholds.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>118 of 197 individuals with SCD from the Fundaci\u00f3 ACE Healthy Brain Initiative underwent three [<jats:sup>18<\/jats:sup>F]florbetaben scans and the remaining 79 underwent two scans in a 5-year span. Individuals were categorised based on baseline Centiloid values (CL) into amyloid positive (A\u03b2+; CL &gt;\u200935.7), Grey Zone (GZ; 20 &lt;\u2009CL \u2264\u200935.7), and amyloid negative (A\u03b2-; CL \u2264\u200920). Relationship between conversion to mild cognitive decline (MCI) and baseline amyloid levels was assessed. Then, to focus on sub-threshold individuals with amyloid accumulation, the A\u03b2- group was split into two groups (N1 (CL \u2264\u200913.5) and N2 (13.5 &lt;\u2009CL \u2264\u200920)), A\u03b2 accumulation was determined, and a parametric image analysis of the A\u03b2 accumulators in the N1 group was performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>At baseline, 20 individuals were A\u03b2+, 8 GZ, 160 N1, and 9 N2. Higher A\u03b2 load, older and less educated individuals presented increased risk of MCI-conversion. Longitudinally, 19% of N1 individuals were accumulators despite very low A\u03b2 burden at baseline. Meanwhile, 89% of the N2 group accumulated A\u03b2 as well as all GZ individuals (which had the highest rate of amyloid accumulation, 5.1 CL\/year). In the parametric image analysis of N1 accumulators, a region within the precuneus was linked to increased A\u03b2 over time.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Baseline amyloid levels differentiate individuals who accumulate amyloid over time and that are at risk for cognitive decline, including those at sub-threshold levels of A\u03b2. This can be valuable to identify pre-clinical AD in a SCD population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-025-07270-7","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T20:38:53Z","timestamp":1745354333000},"page":"3578-3590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9505-4869","authenticated-orcid":false,"given":"Guilherme Domingues","family":"Kolinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9679-0670","authenticated-orcid":false,"given":"Oscar","family":"Sotolongo-Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5583-8837","authenticated-orcid":false,"given":"N\u00faria","family":"Ro\u00e9-Vellv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7548-2687","authenticated-orcid":false,"given":"Juan Pablo","family":"Tartari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7501-9895","authenticated-orcid":false,"given":"\u00c1ngela","family":"Sanabria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7583-8201","authenticated-orcid":false,"given":"Norman","family":"Koglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5052-6586","authenticated-orcid":false,"given":"Andrew W.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8164-9500","authenticated-orcid":false,"given":"Montserrat","family":"Alegret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8423-946X","authenticated-orcid":false,"given":"Llu\u00eds","family":"T\u00e1rraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miren Jone","family":"Gurruchaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2633-2495","authenticated-orcid":false,"given":"Agust\u00edn","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-3009","authenticated-orcid":false,"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5669-269X","authenticated-orcid":false,"given":"Santiago","family":"Bullich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-0950","authenticated-orcid":false,"given":"Marta","family":"Marqui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the FACEHBI study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Alarc\u00f3n-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Alegret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Alllu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bay\u00f3n-Bujan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Berthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bl\u00e1zquez-Folch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Buendia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bullich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Calm-Salvans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Casales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ca\u00f1abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ca\u00f1ada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"de Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Diego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Domingues-Kolinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. V.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gailhajenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"G\u00f3mez-Chiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Guitart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. C.","family":"Guti\u00e9rrez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ibarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lafuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lome\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Marqui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Morera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Montrreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mu\u00f1oz-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ni\u00f1erola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. B.","family":"Nogales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Oliv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Orellana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"P\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pelej\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"P\u00e9rez-Cordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"P\u00e9rez-Grijalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pascual-Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Perissinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Preckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Puerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pytel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. I.","family":"Ramis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ro\u00e9-Vellv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rosende-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sanabria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sanz-Cartagena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sarasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Seguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Sotolongo-Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Tartari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"T\u00e1rraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Tejero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Terencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the AMYPAD consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"7270_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","volume":"11","author":"G Klein","year":"2019","unstructured":"Klein G, Delmar P, Voyle N, Rehal S, Hofmann C, Abi-Saab D, et al. Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: a PET substudy interim analysis. Alzheimers Res Ther. 2019;11:101.","journal-title":"Alzheimers Res Ther"},{"key":"7270_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13195-021-00807-6","volume":"13","author":"S Bullich","year":"2021","unstructured":"Bullich S, Ro\u00e9-Vellv\u00e9 N, Marqui\u00e9 M, Landau SM, Barthel H, Villemagne VL, et al. Early detection of amyloid load using 18F-florbetaben PET. Alzheimers Res Ther. 2021;13:67.","journal-title":"Alzheimers Res Ther"},{"key":"7270_CR3","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00259-020-05187-x","volume":"48","author":"M Cotta Ramusino","year":"2021","unstructured":"Cotta Ramusino M, Perini G, Altomare D, Barbarino P, Weidner W, Salvini Porro G, et al. Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. Eur J Nucl Med Mol Imaging. 2021;48:2157\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7270_CR4","doi-asserted-by":"publisher","first-page":"e067114","DOI":"10.1002\/alz.067114","volume":"18","author":"DV Garc\u00eda","year":"2022","unstructured":"Garc\u00eda DV, Collij LE, Mastenbroek SE, Alves IL, Gispert JD, Ritchie CW, et al. First results of the AMYPAD Prognostic and Natural History Study: amyloid-PET Centiloid predicts cognitive functioning in a pre-dementia population. Alzheimers Dement. 2022;18:e067114.","journal-title":"Alzheimers Dement"},{"key":"7270_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, et al. Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14:191.","journal-title":"Alzheimers Res Ther"},{"key":"7270_CR6","doi-asserted-by":"publisher","unstructured":"Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvad\u00f3 G, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022 [cited 2022 Jul 12]. https:\/\/doi.org\/10.1007\/s00259-022-05784-y.","DOI":"10.1007\/s00259-022-05784-y"},{"key":"7270_CR7","doi-asserted-by":"publisher","unstructured":"Altomare D, Barkhof F, Caprioglio C, Collij LE, Scheltens P, Lopes Alves I, et al. Clinical effect of early vs late amyloid positron emission tomography in memory clinic patients: the AMYPAD-DPMS randomized clinical trial. JAMA Neurol. 2023 [cited 2023 May 10]. https:\/\/doi.org\/10.1001\/jamaneurol.2023.0997.","DOI":"10.1001\/jamaneurol.2023.0997"},{"key":"7270_CR8","doi-asserted-by":"publisher","first-page":"e082733","DOI":"10.1002\/alz.082733","volume":"19","author":"M Mintun","year":"2023","unstructured":"Mintun M, Ritchie CW, Solomon P, Sims JR, Salloway S, Hansson O, et al. Donanemab in early symptomatic Alzheimer\u2019s Disease: efficacy and safety in TRAILBLAZER-ALZ 2, a phase 3 randomized clinical trial. Alzheimers Dement. 2023;19:e082733.","journal-title":"Alzheimers Dement"},{"key":"7270_CR9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Ch\u00e9telat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2014;10:844\u201352.","journal-title":"Alzheimers Dement"},{"key":"7270_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack","year":"2010","unstructured":"Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9:119\u201328.","journal-title":"Lancet Neurol"},{"key":"7270_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack","year":"2013","unstructured":"Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Update on hypothetical model of Alzheimer\u2019s disease biomarkers. Lancet Neurol. 2013;12:207\u201316.","journal-title":"Lancet Neurol"},{"key":"7270_CR12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12:357\u201367.","journal-title":"Lancet Neurol"},{"key":"7270_CR13","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.jalz.2010.05.211","volume":"6","author":"CM Clark","year":"2010","unstructured":"Clark CM, Schneider JA, Mintun MMA, Bedell BJ, Beach TG, Sadowsky CH, et al. O1\u201302-03: Phase III trial results for the amyoid PET imaging agent Florbetapir F 18 (18F-AV-45): imaging to histopathologic correlations in an end-of-life human subject study. Alzheimers Dement. 2010;6:S71\u2013S71.","journal-title":"Alzheimers Dement"},{"key":"7270_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287\u201394.","journal-title":"JAMA Neurol"},{"key":"7270_CR15","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: Phase 3 study. Alzheimers Dement. 2015;11:964\u201374.","journal-title":"Alzheimers Dement"},{"key":"7270_CR16","doi-asserted-by":"publisher","first-page":"e1512","DOI":"10.1212\/WNL.0000000000009216","volume":"94","author":"T Guo","year":"2020","unstructured":"Guo T, Landau SM, Jagust WJ, Initiative for the AND. Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults. Neurology. 2020;94:e1512-24.","journal-title":"Neurology."},{"key":"7270_CR17","doi-asserted-by":"publisher","unstructured":"Jovalekic A, Ro\u00e9-Vellv\u00e9 N, Koglin N, Quintana ML, Nelson A, Diemling M, et al. Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods. Eur J Nucl Med Mol Imaging. 2023 [cited 2023 Sep 5]. https:\/\/doi.org\/10.1007\/s00259-023-06279-0.","DOI":"10.1007\/s00259-023-06279-0"},{"key":"7270_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1-15.e4.","journal-title":"Alzheimers Dement"},{"key":"7270_CR19","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00259-017-3749-6","volume":"44","author":"CC Rowe","year":"2017","unstructured":"Rowe CC, Dor\u00e9 V, Jones G, Baxendale D, Mulligan RS, Bullich S, et al. 18F-Florbetaben PET beta-amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging. 2017;44:2053\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7270_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2967\/jnumed.119.235879","volume":"61","author":"E Fantoni","year":"2020","unstructured":"Fantoni E, Collij L, Alves IL, Buckley C, Farrar G. The spatial-temporal ordering of amyloid pathology and opportunities for PET imaging. J Nucl Med. 2020;61:166\u201371.","journal-title":"J Nucl Med"},{"key":"7270_CR21","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1002\/alz.13761","volume":"20","author":"A Bollack","year":"2024","unstructured":"Bollack A, Collij LE, Garc\u00eda DV, Shekari M, Altomare D, Payoux P, et al. Investigating reliable amyloid accumulation in Centiloids: results from the AMYPAD prognostic and natural history study. Alzheimers Dement. 2024;20:3429\u201341.","journal-title":"Alzheimers Dement."},{"key":"7270_CR22","doi-asserted-by":"crossref","unstructured":"Shekari M, V\u00e1llez Garc\u00eda D, Collij LE, Altomare D, Heeman F, Pemberton H, N\u00faria Ro\u00e9 Vellv\u00e9, et al. Stress testing the centiloid: precision and variability of PET quantification of amyloid pathology. Alzheimers Dement. 2024;20(8):5102\u201313.","DOI":"10.1002\/alz.13883"},{"key":"7270_CR23","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","volume":"79","author":"S Shcherbinin","year":"2022","unstructured":"Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, et al. Association of amyloid reduction after donanemab treatment with Tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79:1015\u201324.","journal-title":"JAMA Neurol"},{"key":"7270_CR24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"7270_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13195-018-0444-1","volume":"10","author":"I de Rojas","year":"2018","unstructured":"de Rojas I, Romero J, Rodr\u00edguez-Gomez O, Pesini P, Sanabria A, P\u00e9rez-Cordon A, et al. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundaci\u00f3 ACE Healthy Brain Initiative (FACEHBI). Alzheimers Res Ther. 2018;10:119.","journal-title":"Alzheimers Res Ther"},{"key":"7270_CR26","doi-asserted-by":"publisher","first-page":"e045780","DOI":"10.1002\/alz.045780","volume":"16","author":"I de Rojas","year":"2020","unstructured":"de Rojas I, Fandos N, Romero J, Pesini P, Marqui\u00e9 M, Tartari JP, et al. The A\u03b242\/A\u03b240 ratio in plasma is associated with amyloid-PET status and rate of progression in individuals with subjective cognitive decline: the Fundaci\u00f3 ACE Healthy Brain Initiative. Alzheimers Dement. 2020;16:e045780.","journal-title":"Alzheimers Dement"},{"key":"7270_CR27","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1523\/JNEUROSCI.0485-18.2018","volume":"38","author":"SL Leal","year":"2018","unstructured":"Leal SL, Lockhart SN, Maass A, Bell RK, Jagust WJ. Subthreshold amyloid predicts tau deposition in aging. J Neurosci. 2018;38:4482\u20139.","journal-title":"J Neurosci"},{"key":"7270_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13195-020-00602-9","volume":"12","author":"M Marqui\u00e9","year":"2020","unstructured":"Marqui\u00e9 M, Valero S, Castilla-Marti M, Mart\u00ednez J, Rodr\u00edguez-G\u00f3mez O, Sanabria \u00c1, et al. Association between retinal thickness and \u03b2-amyloid brain accumulation in individuals with subjective cognitive decline: Fundaci\u00f3 ACE Healthy Brain Initiative. Alzheimers Res Ther. 2020;12:37.","journal-title":"Alzheimers Res Ther"},{"key":"7270_CR29","first-page":"e12127","volume":"12","author":"G S\u00e1nchez-Benavides","year":"2020","unstructured":"S\u00e1nchez-Benavides G, Salvad\u00f3 G, Arenaza-Urquijo EM, Grau-Rivera O, Su\u00e1rez-Calvet M, Mil\u00e0-Alom\u00e0 M, et al. Quantitative informant- and self-reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE \u03b54. Alzheimers Dement Diagn Assess Dis Monit. 2020;12:e12127.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"7270_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13195-021-00877-6","volume":"13","author":"G Ortega","year":"2021","unstructured":"Ortega G, Espinosa Alegret M, Mont\u00e9-Rubio GC, Sotolongo-Grau O, Sanabria A, et al. Combination of white matter hyperintensities and A\u03b2 burden is related to cognitive composites domain scores in subjective cognitive decline: the FACEHBI cohort. Alzheimers Res Ther. 2021;13:141.","journal-title":"Alzheimers Res Ther"},{"key":"7270_CR31","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/alz.12886","volume":"19","author":"LE Collij","year":"2023","unstructured":"Collij LE, Salvad\u00f3 G, de Wilde A, Altomare D, Shekari M, Gispert JD, et al. Quantification of [18F]florbetaben amyloid-PET imaging in a mixed memory clinic population: the ABIDE project. Alzheimers Dement. 2023;19:2397\u2013407.","journal-title":"Alzheimers Dement"},{"key":"7270_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-022-01143-z","volume":"15","author":"M Pascual-Lucas","year":"2023","unstructured":"Pascual-Lucas M, Allu\u00e9 JA, Sarasa L, Fandos N, Castillo S, Terencio J, et al. Clinical performance of an antibody-free assay for plasma A\u03b242\/A\u03b240 to detect early alterations of Alzheimer\u2019s disease in individuals with subjective cognitive decline. Alzheimers Res Ther. 2023;15:2.","journal-title":"Alzheimers Res Ther"},{"key":"7270_CR33","doi-asserted-by":"publisher","first-page":"e208053","DOI":"10.1212\/WNL.0000000000208053","volume":"102","author":"M H\u00f6nig","year":"2024","unstructured":"H\u00f6nig M, Altomare D, Caprioglio C, Collij L, Barkhof F, Van Berckel B, et al. Association between years of education and amyloid burden in patients with subjective cognitive decline, MCI, and Alzheimer disease. Neurology. 2024;102:e208053.","journal-title":"Neurology"},{"key":"7270_CR34","first-page":"100","volume":"4","author":"O Rodriguez-Gomez","year":"2017","unstructured":"Rodriguez-Gomez O, Sanabria A, Perez-Cordon A, Sanchez-Ruiz D, Abdelnour C, Valero S, et al. FACEHBI: a prospective study of risk factors, biomarkers and cognition in a cohort of individuals with subjective cognitive decline. Study rationale and research protocols. J Prev Alzheimers Dis. 2017;4:100\u20138.","journal-title":"J Prev Alzheimers Dis."},{"key":"7270_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"7270_CR36","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S0028-3932(01)00055-0","volume":"39","author":"R Blesa","year":"2001","unstructured":"Blesa R, Pujol M, Aguilar M, Santacruz P, Bertran-Serra I, Hern\u00e1ndez G, et al. Clinical validity of the \u2018mini-mental state\u2019 for Spanish speaking communities. Neuropsychologia. 2001;39:1150\u20137.","journal-title":"Neuropsychologia"},{"key":"7270_CR37","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The Clinical Dementia Rating (CDR). Neurology. 1993;43:2412\u20132412-a.","journal-title":"Neurology."},{"key":"7270_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/13803395.2011.630652","volume":"34","author":"M Alegret","year":"2012","unstructured":"Alegret M, Espinosa A, Vinyes-Junqu\u00e9 G, Valero S, Hern\u00e1ndez I, T\u00e1rraga L, et al. Normative data of a brief neuropsychological battery for Spanish individuals older than 49. J Clin Exp Neuropsychol. 2012;34:209\u201319.","journal-title":"J Clin Exp Neuropsychol"},{"key":"7270_CR39","doi-asserted-by":"publisher","first-page":"e76436","DOI":"10.1371\/journal.pone.0076436","volume":"8","author":"M Alegret","year":"2013","unstructured":"Alegret M, Espinosa A, Valero S, Vinyes-Junqu\u00e9 G, Ruiz A, Hern\u00e1ndez I, et al. Cut-off Scores of a Brief Neuropsychological Battery (NBACE) for Spanish individual adults older than 44 years old. PLoS ONE. 2013;8:e76436.","journal-title":"PLoS ONE"},{"key":"7270_CR40","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1080\/13803395.2012.666230","volume":"34","author":"RE Amariglio","year":"2012","unstructured":"Amariglio RE, Frishe K, Olson LE, Wadsworth LP, Lorius N, Sperling RA, et al. Validation of the face name associative memory exam in cognitively normal older individuals. J Clin Exp Neuropsychol. 2012;34:580\u20137.","journal-title":"J Clin Exp Neuropsychol"},{"key":"7270_CR41","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/arclin\/acv050","volume":"30","author":"M Alegret","year":"2015","unstructured":"Alegret M, Valero S, Ortega G, Espinosa A, Sanabria A, Hern\u00e1ndez I, et al. Validation of the Spanish Version of the Face Name Associative Memory Exam (S-FNAME) in cognitively normal older individuals. Arch Clin Neuropsychol. 2015;30:712\u201320.","journal-title":"Arch Clin Neuropsychol"},{"key":"7270_CR42","unstructured":"EMA. Neuraceq SmPC [Internet]. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/neuraceq-epar-product-information_en.pdf. Accessed 3 June 2024."},{"key":"7270_CR43","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1006\/nimg.2001.0978","volume":"15","author":"N Tzourio-Mazoyer","year":"2002","unstructured":"Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273\u201389.","journal-title":"Neuroimage"},{"key":"7270_CR44","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1002\/hbm.25121","volume":"41","author":"I Jelistratova","year":"2020","unstructured":"Jelistratova I, Teipel SJ, Grothe MJ. Longitudinal validity of PET-based staging of regional amyloid deposition. Hum Brain Mapp. 2020;41:4219\u201331.","journal-title":"Hum Brain Mapp"},{"key":"7270_CR45","doi-asserted-by":"publisher","first-page":"e1692","DOI":"10.1212\/WNL.0000000000200148","volume":"98","author":"LE Collij","year":"2022","unstructured":"Collij LE, Salvad\u00f3 G, Wottschel V, Mastenbroek SE, Schoenmakers P, Heeman F, et al. Spatial-temporal patterns of \u03b2-amyloid accumulation. Neurology. 2022;98:e1692\u2013703.","journal-title":"Neurology"},{"key":"7270_CR46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12883-017-0846-x","volume":"17","author":"CA Lane","year":"2017","unstructured":"Lane CA, Parker TD, Cash DM, Macpherson K, Donnachie E, Murray-Smith H, et al. Study protocol: Insight 46 \u2013 a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurol. 2017;17:75.","journal-title":"BMC Neurol"},{"key":"7270_CR47","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","volume":"52","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with 18 F-Florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210\u20137.","journal-title":"J Nucl Med"},{"key":"7270_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","volume":"3","author":"O Sabri","year":"2015","unstructured":"Sabri O, Seibyl J, Rowe C, Barthel H. Beta-amyloid imaging with florbetaben. Clin Transl Imaging. 2015;3:13\u201326.","journal-title":"Clin Transl Imaging"},{"key":"7270_CR49","unstructured":"EMA. Qualification opinion for Centiloid measure of Amyloid PET to quantify brain amyloid deposition [internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/qualification-opinion-centiloid-measureamyloid-pet-quantify-brain-amyloid-deposition_en.pdf. Accessed 30 June 2024."},{"key":"7270_CR50","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1007\/s00259-021-05201-w","volume":"48","author":"EE Verwer","year":"2021","unstructured":"Verwer EE, Golla SSV, Kaalep A, Lubberink M, van Velden FHP, Bettinardi V, et al. Harmonisation of PET\/CT contrast recovery performance for brain studies. Eur J Nucl Med Mol Imaging. 2021;48:2856\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7270_CR51","first-page":"3176","volume":"63","author":"S Li","year":"2022","unstructured":"Li S, Bourgeat P, Lebrat L, O\u2019Keefe G, Fripp J, Villemagne V, et al. Centiloid harmonisation across PET cameras without using paired data. J Nucl Med. 2022;63:3176\u20133176.","journal-title":"J Nucl Med"},{"key":"7270_CR52","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40658-023-00588-x","volume":"10","author":"M Shekari","year":"2023","unstructured":"Shekari M, Verwer EE, Yaqub M, Daamen M, Buckley C, Frisoni GB, et al. Harmonization of brain PET images in multi-center PET studies using Hoffman phantom scan. EJNMMI Phys. 2023;10:68.","journal-title":"EJNMMI Phys"},{"issue":"7","key":"7270_CR53","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.2967\/jnumed.123.267150","volume":"65","author":"EE Lecy","year":"2024","unstructured":"Lecy EE, Min H-K, Apgar CJ, Maltais DD, Lundt ES, Albertson SM, Senjem ML, et al. Patterns of early neocortical amyloid-\u03b2 accumulation: a PET population-based study. J Nucl Med. 2024;65(7):1122\u20138.","journal-title":"J Nucl Med"},{"key":"7270_CR54","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s00259-020-04773-3","volume":"47","author":"MS Baek","year":"2020","unstructured":"Baek MS, Cho H, Lee HS, Choi JY, Lee JH, Ryu YH, et al. Temporal trajectories of in vivo tau and amyloid-\u03b2 accumulation in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2020;47:2879\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7270_CR55","doi-asserted-by":"publisher","first-page":"e1837","DOI":"10.1212\/WNL.0000000000207770","volume":"101","author":"RR Pittock","year":"2023","unstructured":"Pittock RR, Aakre JA, Castillo AM, Ramanan VK, Kremers WK, Jack CR, et al. Eligibility for anti-amyloid treatment in a population-based study of cognitive aging. Neurology. 2023;101:e1837\u201349.","journal-title":"Neurology"},{"issue":"20","key":"7270_CR56","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1212\/WNL.0000000000004643","volume":"89","author":"MJ Grothe","year":"2017","unstructured":"Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ, Initiative ADN, Initiative ADN. In vivo staging of regional amyloid deposition. Neurology. 2017;89(20):2031\u20138.","journal-title":"Neurology"},{"issue":"11","key":"7270_CR57","doi-asserted-by":"publisher","first-page":"e1538","DOI":"10.1212\/WNL.0000000000010256","volume":"95","author":"LE Collij","year":"2020","unstructured":"Collij LE, Heeman F, Salvad\u00f3 G, Ingala S, Altomare D, de Wilde A, Konijnenberg E, et al. Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology. 2020;95(11):e1538\u201353.","journal-title":"Neurology"},{"key":"7270_CR58","doi-asserted-by":"publisher","unstructured":"Collij LE, Bollack A, La Joie R, Shekari M, Bullich S, Ro\u00e9\u2010Vellv\u00e9 N, Koglin N, Jovalekic A, Garcia DV, Drzezga A, Garibotto V. Centiloid recommendations for clinical context\u2010of\u2010use from the AMYPAD consortium. Alzheimers Dementia. 2024. https:\/\/doi.org\/10.1002\/alz.086564.","DOI":"10.1002\/alz.086564"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07270-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07270-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07270-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:27:13Z","timestamp":1757168833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07270-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7270"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07270-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A written consent was obtained from all participants prior to the enrolment in the study. The FACEHBI protocol received approval from the ethics committees of Hospital Cl\u00ednic i Provincial in Barcelona, Spain (EudraCT number 2014\u201300079 -\u200938). The referral centre ethics committee approved the patient recruitment, and collection protocols were in accordance with ethical standards according to World Medical Association Declaration of Helsinki\u2014Ethical Principles for Medical Research Involving Human Subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"AR is member of the scientific advisory board of Landsteiner Genmed and Grifols SA. AR has stocks of Landsteiner Genmed.MB has consulted for Araclon, Avid, Grifols, Lilly, Nutricia, Roche, Eisai and Servier. She received fees from lectures and funds for research from Araclon, Biogen, Grifols, Nutricia, Roche and Servier. She reports grants\/research funding from Abbvie, Araclon, Biogen Research Limited, Bioiberica, Grifols, Lilly, S.A, Merck Sharp & Dohme, Kyowa Hakko Kirin, Laboratorios Servier, Nutricia SRL, Oryzon Genomics, Piramal Imaging Limited, Roche Pharma SA, and Schwabe Farma Iberica SLU, all outside the submitted work. She has not received personal compensations from these organizations.MM has consulted for F. Hoffmann-La Roche Ltd and is a member of the Scientific Advisory Board of Biomarkers of Araclon.GDK, NRV, EPM, NK, AS and SB are employees of Life Molecular Imaging GmbH.The rest of authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}